Enveric Biosciences (NASDAQ:ENVB) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Enveric Biosciences (NASDAQ:ENVB) from a hold rating to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Enveric Biosciences Stock Performance

Shares of ENVB opened at $1.48 on Friday. The firm has a market capitalization of $5.45 million, a price-to-earnings ratio of -0.06 and a beta of 1.13. Enveric Biosciences has a one year low of $1.25 and a one year high of $17.64. The stock’s fifty day moving average is $1.43 and its 200-day moving average is $2.08.

Enveric Biosciences (NASDAQ:ENVB) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.